AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion — Jun 30th, 2025

BUSINESS AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker’s planned acquisition includes CPTX2309, which is currently in Phase 1 and in development for the treatment of B cell-mediated autoimmune disease...

AbbVie's migraine drug meets main goal in head-to-head study with topiramate — Jun 18th, 2025

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to head late-stage trial. The U.S. drugmaker has been expanding and banking on its neuroscience portfolio after its blockbuster arthritis drug Humira began...

Morgan Stanley reiterates Overweight rating on AbbVie stock at $250 — Jun 30th, 2025

Investing.com - Morgan Stanley has reiterated an Overweight rating and $250.00 price target on AbbVie (NYSE:ABBV), a prominent player in the Biotechnology industry with a market capitalization of $326.4 billion, following the company’s acquisition announcement. According to InvestingPro ...

Lower interest rates, drug pricing reform clarity are catalysts for biotech M&A market — Jun 19th, 2025

[Wooden blocks with text M and A on light blue paper, business concept. MA - short for mergers and acquisitions] While the biotech M&A market is down from the juggernaut of deals done in 2019 and their high valuations, that could change later this year, assuming the Federal Reserve lowers...

Validea Detailed Fundamental Analysis - ABBV — Jun 20th, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characterist...

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? — Jun 18th, 2025

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the Invesco Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on 06/23/2005. Passively managed ETFs are becoming increasingly popular with institutional as we...

Top Midday Stories: Hewlett Packard, Juniper Settle Antitrust Suit With DOJ; Home Depot Unit Acquires GMS for $5.5 Billion — Jun 30th, 2025

All three major US stock indexes were up in late-morning trading Monday after Canada announced late PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscripti...

ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B — Jul 1st, 2025

AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Capstan Therapeutics, for up to $2.1 billion in cash. The impending acquisition will add Capstan’s lead asset, CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T thera...

FDA accepts Allergan's application for neck line treatment — Jun 30th, 2025

IRVINE, Calif. - The U.S. Food and Drug Administration has accepted for review Allergan Aesthetics’ supplemental premarket approval application for SKINVIVE by JUVEDERM to reduce neck lines, the AbbVie company (NYSE:ABBV) announced Monday. AbbVie, with its robust market capitalization of...

FDA Accepts For Review Allergan Aesthetics Premarket Approval Application For Skinvive By Juvéderm — Jun 30th, 2025

(RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), Monday announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental premarket approval (sPMA) application for Skinvive by Juvéderm to reduce neck lines for the improvement of neck appearance. Sk...

Guru Fundamental Report for ABBV — Jun 22nd, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characterist...

Got $500? 2 Healthcare Stocks to Buy and Hold Forever — Jun 28th, 2025

I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence (AI) will replace millions of jobs. But there's one thing I'm quite confident about: We'll still need healthcare products and ser...

Palantir, Circle Internet Surge Among Monday's Market Cap Stock Movers — Jun 30th, 2025

Monday’s trading session has seen notable movements in the stock market, with some stocks experiencing significant intra-day volatility. Mega-cap stock Palantir Technologies Inc (NASDAQ:PLTR) has soared following a strategic partnership announcement, while large-cap Circle Internet Gro...

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)? — Jul 1st, 2025

The Fidelity MSCI Health Care Index ETF (FHLC) was launched on 10/21/2013, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Broad segment of the equity market. An increasingly popular option among retail and institutional investors, pass...

AbbVie succeeds in late-stage migraine treatment trial — Jun 18th, 2025

[Anatomical 3D illustration of the transparent human head interior.] AntonioGuillem AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) said on Wednesday that its late-stage study testing atogepant in comparison with the highest dose of topiramate for migraine treatment met the main...

Sector Update: Health Care Stocks Higher Late Afternoon — Jun 30th, 2025

Health care stocks rose late Monday afternoon with the NYSE Health Care Index up 0.4% and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscript...

U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance — Jun 30th, 2025

SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness. If approved, SKINVIVE by JUVÉDERM® will be the first hyaluronic acid injectable treatment option aiming to reduce neck line...

Why AbbVie (ABBV) is a Top Value Stock for the Long-Term — Jul 2nd, 2025

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing m...

AbbVie to Host Second-Quarter 2025 Earnings Conference Call — Jun 30th, 2025

NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible...

Exploring 3 High Growth Tech Stocks In The US Market — Jul 2nd, 2025

The United States market has shown a positive trajectory, climbing 2.9% in the last week and up 14% over the past year, with earnings anticipated to grow by 15% annually in the coming years. In this context of robust market performance, identifying high growth tech stocks involves looking ...

Is AbbVie the Best Dividend Stock in Big Pharma Today? — Jun 21st, 2025

AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track record makes a dividend cut highly unlikely, as it would break the streak and potentially take...

3 Dividend Stocks to Double Up on Right Now — Jun 29th, 2025

Investors looking for dividend stocks to buy often stop with a high dividend yield. A good dividend stock, however, may not yield much but pays you regularly -- and even better, pays you more and more with time. That's the only real way to earn income from dividend stocks. And once you und...

Is AbbVie the Best Dividend Stock in Big Pharma Today? — Jun 21st, 2025

AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track record makes a dividend cut highly unlikely, as it would break the streak and potentially take...

Guru Fundamental Report for ABBV — Jun 29th, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characterist...

AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant — Jun 18th, 2025

AbbVie recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in migraine treatment. Over the last month, AbbVie’s stock price remained relatively flat, mirroring broader market trends. While the positive study results for Atogepant might have add...

AbbVie to Host Second-Quarter 2025 Earnings Conference Call — Jun 30th, 2025

NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible...

Merck's Upside Potential: Beyond The Keytruda Cliff — Jun 29th, 2025

While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month, we discussed how Keytruda is a ticking time bomb for Merck stock. In this analysis, we focus ...

3 Dividend Stocks to Double Up on Right Now — Jun 29th, 2025

Investors looking for dividend stocks to buy often stop with a high dividend yield. A good dividend stock, however, may not yield much but pays you regularly -- and even better, pays you more and more with time. That's the only real way to earn income from dividend stocks. And once you und...

AbbVie to acquire Capstan Therapeutics for up to $2.1B in cash — Jun 30th, 2025

[Abbvie] vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) has agreed to acquire clinical-stage biotechnology company Capstan Therapeutics for up to $2.1 billion in cash. The transaction is subject to the satisfaction of customary closin...

Top Stock Reports for Alphabet, AbbVie & Walt Disney — Jul 1st, 2025

Tuesday, July 1, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), AbbVie Inc. (ABBV) and The Walt Disney Co. (DIS). These research reports have b...

AbbVie Declares Quarterly Dividend — Jun 20th, 2025

NORTH CHICAGO, Ill., June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable August 15, 2025, to stockholders of record at the close of business on July 15, 2025. Since the...

AbbVie’s Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment — Jun 28th, 2025

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the “Elahere Market Opportunities and Strategies to 2034” report was added to ResearchAndMarkets.com’s offering. It stated that the global market for Elahere, which is a trea...

AbbVie’s Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment — Jun 28th, 2025

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the “Elahere Market Opportunities and Strategies to 2034” report was added to ResearchAndMarkets.com’s offering. It stated that the global market for Elahere, which is a trea...

Will AbbVie's Acquisition Spree Aid Pipeline Growth? — Jul 2nd, 2025

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signing some early-stage deals across various other therapeutic areas, including oncology and neuroscience. Earlier this...

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' — Jun 21st, 2025

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices...

LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet? — Jun 20th, 2025

Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, strong market capitalization and global footprint. Both companies have a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also ...

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention — Jun 18th, 2025

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month1 Atogepant met ...

AbbVie to buy Capstan Therapeutics for up to $2.1 billion — Jun 30th, 2025

(Reuters) -U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion. Capstan develops CAR-T therapies, a type of treatment that uses a patient's own immune cells, specifically T cells, to fight diseases. Its m...

US judge halts Trump administration move to layoff HHS employees — Jul 1st, 2025

[US Department of Health and Human Services] MarioGuti/iStock via Getty Images A U.S. federal judge has put a stop to the Trump administration's plans to significantly downsize the workforce and close several agencies within the U.S. Department of Health and Human Services, Reuters report...

AbbVie declares $1.64 dividend — Jun 20th, 2025

* AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) declares $1.64/share quarterly dividend [https://seekingalpha.com/pr/20142801-abbvie-declares-quarterly-dividend], in line with previous. * Forward yield [https://seekingalpha.com/symbol/ABBV/dividends/yield?source=news_bullet...

Notable healthcare headlines for the week: Novo Nordisk, Amgen and UnitedHealth in focus — Jun 29th, 2025

Wall Street’s major averages closed Friday's trading session higher, as both the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) and Nasdaq Composite (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) notched fresh all-time trading highs and record high closes. The S&P 500 He...

Sector Update: Health Care Stocks Advance Monday Afternoon — Jun 30th, 2025

Health care stocks rose Monday afternoon with the NYSE Health Care Index climbing 0.2% and the Healt PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscript...

ABBV Factor-Based Stock Analysis — Jul 2nd, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characterist...

AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology — Jun 30th, 2025

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseases Propos...

Those who invested in AbbVie (NYSE:ABBV) five years ago are up 126% — Jun 28th, 2025

It hasn't been the best quarter for AbbVie Inc. (NYSE:ABBV) shareholders, since the share price has fallen 11% in that time. But at least the stock is up over the last five years. However we are not very impressed because the share price is only up 84%, less than the market return of 102%....

Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth? — Jul 2nd, 2025

Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary arterial hypertension (PAH) and infectious diseases. J&J is schedu...

Guru Fundamental Report for ABBV — Jun 19th, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characterist...

AbbVie to buy Capstan for up to $2.1 billion in immunology push — Jun 30th, 2025

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases. The U.S. drugmaker has spent over $20 ...

J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications — Jun 23rd, 2025

J&J JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting label expansion to its two key products, Darzalex and Imbruvica, across separate new indications. CHMP Endorses JNJ’s Darzalex for a New Multiple Myeloma Setting The EMA ...

The Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney — Jul 2nd, 2025

For Immediate Release Chicago, IL – July 2, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog incl...